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Clinical PerspectiveWhat Is New?Hypertensive people living with HIV (PLWH) on antiretroviral therapy with long‐term viral suppression exhibit higher levels of circulating eosinophils and the eosinophil maturation marker interleukin‐5 compared with normotensive PLWH.There may be a novel pathway linking eosinophils and hypertension in PLWH, and further studies are warranted to validate and explore this finding.What Are the Clinical Implications?PLWH are at increased risk of cardiovascular disease compared with HIV‐negative people, and the management of hypertension is essential to reducing disease burden in this population.Targeting inflammation, especially eosinophils and their maturation, may provide therapeutic benefit in treating and/or preventing hypertension in PLWH.

Introduction {#jah34782-sec-0008}
============

With the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) can now survive decades, but this success is tempered by an increasing burden of cardiovascular disease in this population.[1](#jah34782-bib-0001){ref-type="ref"}, [2](#jah34782-bib-0002){ref-type="ref"}, [3](#jah34782-bib-0003){ref-type="ref"}, [4](#jah34782-bib-0004){ref-type="ref"} One contributor to the excess cardiovascular mortality in PLWH may be the increased prevalence of hypertension compared with the general population, which persists despite suppression of plasma viremia with ART.[5](#jah34782-bib-0005){ref-type="ref"} Recent evidence suggests that HIV may contribute to hypertension through direct viral effects on the lining of vessels, and indirectly through eliciting an inflammatory cascade that contributes to the genesis and propagation of hypertension and atherosclerosis.[6](#jah34782-bib-0006){ref-type="ref"}

Over the past 50 years, research in several laboratories, including our own, has demonstrated that both the innate and adaptive immune systems contribute to hypertension. T cells infiltrate the kidneys and perivascular space in response to hypertensive stimuli and release inflammatory cytokines that promote renal and vascular dysfunction, leading to elevated blood pressure and end organ damage.[7](#jah34782-bib-0007){ref-type="ref"} However, the mechanisms of inflammation contributing to hypertension are not well explored in PLWH. In this study, we used a well‐characterized cohort of PLWH on long‐term ART to investigate the relationship between immune cell subtypes, soluble biomarkers of inflammation, and prevalent hypertension. We also compared our findings in hypertension in HIV‐negative participants with or without hypertension.

Methods {#jah34782-sec-0009}
=======

Availability of Data and Material {#jah34782-sec-0010}
=================================

The data sets used and/or analyzed during the current study will be made available on request from the corresponding author.

Human Study Population {#jah34782-sec-0011}
----------------------

We used the Adiposity and Immune Activation Cohort of 70 PLWH recruited at the Vanderbilt Comprehensive Care Clinic from 2013 to 2014, who have been previously described.[8](#jah34782-bib-0008){ref-type="ref"}, [9](#jah34782-bib-0009){ref-type="ref"}, [10](#jah34782-bib-0010){ref-type="ref"}, [11](#jah34782-bib-0011){ref-type="ref"}, [12](#jah34782-bib-0012){ref-type="ref"} All subjects were on efavirenz, tenofovir, and emtricitabine (ie, the combination pill Atripla) for at least the 6 months before enrollment, and had been on ART with persistent HIV‐1 RNA measurements \<50 copies/mL for at least the previous 2 years. All participants were nondiabetic, with no history of acute coronary events, stroke, known rheumatologic or inflammatory conditions (aside from HIV), or concomitant comorbidities that might modify eosinophil counts (allergic rhinitis, asthma, dermatoses, and parasitic disease). Use of antihypertensive medication at the time of the study visit and/or \>2 sequential outpatient systolic blood pressure measurements \>140 mm Hg preceding the visit were used to classify hypertension status. A cohort of 50 HIV‐negative people, also from Vanderbilt University Medical Center, served as controls. Data on this cohort were obtained by review of medical records of volunteers who provided consent for participation in research conducted at the Division of Clinical Pharmacology. Data in normotensive and hypertensive HIV‐negative subjects with available differential counts of white blood cells were collected, eliminating participants with comorbidities known to modify eosinophil counts, such as allergic rhinitis, asthma, dermatoses, and parasitic disease. Each subject could have ≥1 eosinophil count over time (mean, 3.9±0.4; median, 3). If counts were \>1, values were averaged. As an additional HIV‐negative control cohort, individuals of interest were sought in the Synthetic Derivative, a Vanderbilt University Medical Center database of \~2.5×10^6^ deidentified electronic medical records. The search strategy consisted of identifying subjects without HIV/AIDS and dividing them by the presence versus absence of essential hypertension diagnostic codes. Only subjects containing ≥1 data point on eosinophil counts and body mass indexes (BMIs) were used. Exclusion criteria were all diseases known to produce eosinophilia, including but not limited to respiratory and cutaneous allergic disorders, hematologic malignancies, some infections, collagen vascular disorders, and ages \<30 years and \>60 years. For subjects with \>1 measurement of eosinophils or BMI, all values were averaged. All participants provided written informed consent, and the study was approved by the Vanderbilt Institutional Review Board.

Inflammatory Biomarker Assessment {#jah34782-sec-0012}
---------------------------------

Venous blood was drawn in the morning between 8 and 11 [am]{.smallcaps} and after a minimum 8‐hour fast. Samples were collected in an EDTA‐containing vacutainer and centrifuged for 10 minutes at 4°C, and the plasma was removed and immediately frozen at −80°C. Plasma levels of soluble cluster of differentiation (sCD) 14 and sCD163, 2 surface markers released into circulation by activated macrophages, were measured using ELISA (R&D Systems, Minneapolis, MN). Other plasma cytokines and immune biomarkers, including interleukins, MCP1 (monocyte chemoattractant protein‐1), MIP‐1α/β (macrophage inflammatory protein‐1 α and β), tumor necrosis factor‐α (TNF‐α), and soluble TNF‐α receptors 1 and 2 (sTNFR1 and sTNFR2, respectively), as well as vascular cell adhesion molecule‐1 and intercellular adhesion molecule‐1 (ICAM‐1), were measured in duplicate using a standard multiple immunoassay panel (MesoScale, Rockville, MD).

Flow Cytometry {#jah34782-sec-0013}
--------------

Peripheral blood mononuclear cells were obtained from fasting whole blood samples, as previously described.[10](#jah34782-bib-0010){ref-type="ref"} Flow cytometry was performed using the Fortessa (Becton Dickson Biosciences) flow cytometer to measure activated, senescent, exhausted, and memory T‐cell subsets using previously described fluorochrome panels.[8](#jah34782-bib-0008){ref-type="ref"}

Eosinophil Counts {#jah34782-sec-0014}
-----------------

Eosinophil counts and percentages were obtained in normotensive and hypertensive participants with and without HIV from automated differential cell counts performed in the Vanderbilt University Medical Center Clinical Laboratory.

Assessment of Body Composition {#jah34782-sec-0015}
------------------------------

A full‐body Dual‐energy X‐ray absorptiometry (GE Lunar Prodigy; GE Healthcare, Little Chalfont, UK) measured total body fat mass to calculate fat mass index (FMI; total fat in kilograms divided by height in meters, squared). FMI is a variant of BMI that accounts for individual variability in the ratio of fat/lean mass.[13](#jah34782-bib-0013){ref-type="ref"} The assessment of FMI is shown in Table [S1](#jah34782-sup-0001){ref-type="supplementary-material"}.

Statistical Analyses {#jah34782-sec-0016}
--------------------

We assessed the normality of data using kurtosis and skewness values as well as graphing using Q‐Q plots. Medians and interquartile ranges were calculated for continuous variables, and percentages were calculated for categorical variables. Demographics, clinical characteristics, and the outcome variables were compared between hypertensive and normotensive people using Mann‐Whitney *U* test or χ^2^ test, as appropriate. We conducted statistical analysis in R software (<http://www.r-project.com>). Logistic regression was performed to analyze the association between hypertension and inflammation markers, with adjustment of age, sex, and FMI/BMI for the HIV‐positive participants and age, sex, and BMI for the HIV‐negative participants. Log2 transformation was performed on variables with highly skewed data distribution. Multiple imputation was performed to impute missing data with Hmisc package in R (cran.r‐project.org/package=Hmisc). No adjustments were made for multiple comparisons for this exploratory study, although results and the potential for false discovery were interpreted in the context of known biological pathways.[14](#jah34782-bib-0014){ref-type="ref"} *P*=0.05 was used to infer statistical significance.

Results {#jah34782-sec-0017}
=======

Clinical characteristics of the HIV‐positive study cohort are shown in Table [1](#jah34782-tbl-0001){ref-type="table"}. In unadjusted comparisons, we observed no significant differences among CD4^+^ and CD8^+^ naïve and memory T‐cell subtypes between hypertensive and normotensive individuals. We also found no significant differences among CD4^+^ and CD8^+^ T cells expressing CD57 and Programmed cell death protein 1. However, we found that hypertension was associated with lower CD4^+^ T cells expressing the CD38 activation marker, but not CD8^+^ CD38^+^ T cells, and there were no significant differences in dual‐expressing CD38^+^ and Human Leukocyte Antigen -- DR isotype^+^ cells (Figure [S1](#jah34782-sup-0001){ref-type="supplementary-material"}). The gating strategy to identify T‐cell subpopulations is shown in Figure [S2](#jah34782-sup-0001){ref-type="supplementary-material"}.

###### 

HIV‐Positive Participant Characteristics

  Variables                                               Total Participants (n=70)                                           
  ------------------------------------------------------- --------------------------- ------------------- ------------------- ------------------------------------------------
  Age, median (IQR), y                                    42 (35--47)                 43 (35--47)         49 (43--52)         0.002[a](#jah34782-note-0003){ref-type="fn"}
  Women, n (%)                                            30 (43)                     16 (41)             14 (45)             0.810
  Duration on treatment, median (IQR), y                  6.2 (4.3--10.1)             6.1 (4.3--11.1)     6.4 (4.3--8.2)      0.804
  BMI, median (IQR), kg/m^2^                              32.3 (26.3--37.1)           26.5 (22.8--32.8)   33.9 (28.2--40.0)   0.001[a](#jah34782-note-0003){ref-type="fn"}
  FMI×10^3^, median (IQR)                                 12.8 (8.8--16.3)            8.8 (5.7--13.2)     13.3 (9.9--17.5)    0.003[a](#jah34782-note-0003){ref-type="fn"}
  CD4^+^ count, median (IQR), cells/μL                    701 (540--953)              700 (523--924)      690 (581--969)      0.554
  Nadir CD4^+^ count, median (IQR), cells/μL              257 (140--378)              276 (183--393)      240 (100--371)      0.301
  CD8^+^ count, median (IQR), cells/μL                    752 (600--1004)             774 (630--949)      675 (585--1062)     0.582
  Smokers, n (%)                                          25 (36)                     14 (36)             11 (35)             1.000
  Cigarettes per day (N=69), median (IQR)                 0.0 (0.0--4.0)              0.0 (0.0--4.0)      0.0 (0.0--4.0)      0.787
  Nonwhite, n (%)                                         38 (54)                     23 (59)             15 (48)             1.000
  Hepatitis C infection, n (%)                            8 (11)                      2 (5)               6 (19)              0.127
  Fasting total cholesterol, median (IQR), mg/dL          176 (154--202)              176 (160--203)      171 (142--200)      0.460
  Fasting LDL, median (IQR), mg/dL                        105 (88--123)               111 (89--123)       101 (85--124)       0.435
  Fasting HDL, median (IQR), mg/dL                        45 (36--52)                 47 (35--55)         43 (36--50)         0.619
  Fasting triglycerides, median (IQR), mg/dL              101 (73--139)               98 (80--147)        102 (73--138)       0.953
  Obese, n (%)                                            35 (50)                     14 (35.9)           21 (67.7)           0.008[a](#jah34782-note-0003){ref-type="fn"}
  Average waist circumference, median (IQR), cm           104 (88--122)               96 (82--110)        114 (101--128)      0.001[a](#jah34782-note-0003){ref-type="fn"}
  Average mid‐upper arm circumference, median (IQR), cm   33 (30--36)                 31 (28--35)         35 (31--38)         0.006[a](#jah34782-note-0003){ref-type="fn"}
  Visceral adipose tissue, median (IQR), cm               1554 (630--2219)            906 (381--2061)     1950 (1316--3014)   0.002[a](#jah34782-note-0003){ref-type="fn"}
  Taking NSAIDS, n (%)                                    10 (14.3)                   5 (12.8)            5 (16.1)            0.694
  Taking daily aspirin, n (%)                             6 (8.6)                     0 (0.0)             6 (19.4)            0.006
  Highly sensitive CRP, median (IQR), mg/L                2.4 (1.1--6.2)              2.1 (0.8--3.4)      3.2 (1.5--6.6)      0.05
  Amyloid A, median (IQR), pg/mL ×10^6^                   1.8 (0.9--5.0)              1.4 (0.7--2.2)      4.2 (1.8--9.7)      \<0.001[a](#jah34782-note-0003){ref-type="fn"}
  Leptin, median (IQR), ng/mL                             17.3 (8.5--32.1)            11.5 (5.9--30.2)    23.6 (12.4--37.2)   0.02[a](#jah34782-note-0003){ref-type="fn"}
  Adiponectin, median (IQR), pg/mL ×10^6^                 9.9 (5.9--14.6)             10.6 (6.2--18.5)    9.5 (5.4--13.8)     0.200

For quantitative variables age, duration on treatment, BMI, FMI, and CD4 and CD8 counts, we used the Wilcoxon rank sum test; and we used the χ^2^ test for the remaining binary categorical variables. BMI indicates body mass index; CD, cluster of differentiation; CRP, C‐reactive protein; FMI, fat mass index; HDL, high‐density lipoprotein; IQR, interquartile range; LDL, low‐density lipoprotein.

*P*\<0.05.

Increased Macrophage Activation in PLWH Is Associated With Prevalent Hypertension {#jah34782-sec-0018}
---------------------------------------------------------------------------------

We have previously shown that cells of the innate immune system, including monocyte‐derived dendritic cells, are activated during experimental and human hypertension.[15](#jah34782-bib-0015){ref-type="ref"}, [16](#jah34782-bib-0016){ref-type="ref"} We observed no significant difference in sCD14 in normotensive compared with hypertensive participants with HIV (Figure [1](#jah34782-fig-0001){ref-type="fig"}A). However, we found that hypertension was associated with a marked increase in macrophage activation markers and chemokines, including sCD163 (Figure [1](#jah34782-fig-0001){ref-type="fig"}B) and MIP‐1α (Figure [1](#jah34782-fig-0001){ref-type="fig"}C). In addition, we found that hypertension was associated with a significant increase in MCP1 (Figure [1](#jah34782-fig-0001){ref-type="fig"}D) and both vascular cell adhesion molecule‐1 (Figure [1](#jah34782-fig-0001){ref-type="fig"}E) and ICAM‐1 (Figure [1](#jah34782-fig-0001){ref-type="fig"}F). These results suggest that increased macrophage activation and expression of vascular adhesion molecules are a feature of inflammation and hypertension among PLWH on ART.

![Increased macrophage activation in virally suppressed HIV ^+^ participants on antiretroviral therapy is associated with blood pressure elevation. Analysis of monocyte/macrophage activation in plasma using ELISA assay in people living with HIV showing soluble cluster of differentiation (sCD) 14 (**A**), sCD163 (**B**), MIP (macrophage inflammatory protein) (**C**), MCP (monocyte chemoattractant protein) (**D**) and adhesion molecules, including vascular cell adhesion molecule 1 (VCAM‐1) (**E**) and intercellular adhesion molecule 1 (ICAM‐1) (**F**). HTN indicates hypertensive; NT, normotensive. \**P*\<0.05 using the Mann‐Whitney *U* test.](JAH3-9-e011450-g001){#jah34782-fig-0001}

Cytokines Associated With Hypertension in PLWH {#jah34782-sec-0019}
----------------------------------------------

Previous studies have found that inflammatory cytokines, including interleukin‐17, contribute to the development of hypertension.[17](#jah34782-bib-0017){ref-type="ref"}, [18](#jah34782-bib-0018){ref-type="ref"}, [19](#jah34782-bib-0019){ref-type="ref"} We sought to determine if hypertension in PLWH is associated with increased cytokine production. We found that hypertensive PLWH have significantly higher levels of interleukin‐17 (Figure [2](#jah34782-fig-0002){ref-type="fig"}A). We also found that hypertension was associated with increased circulating interleukin‐6 (Figure [2](#jah34782-fig-0002){ref-type="fig"}B). In addition, we observed lower levels of the anti‐inflammatory cytokine interleukin‐10 in hypertensive participants, but this did not reach statistical significance (Figure [2](#jah34782-fig-0002){ref-type="fig"}C). There was no significant difference in plasma TNF‐α or sTNFR2, but we found a significant elevation of sTNFR1 (Figure [2](#jah34782-fig-0002){ref-type="fig"}D through [2](#jah34782-fig-0002){ref-type="fig"}F). Thus, hypertension in PLWH is associated with higher circulating levels of interleukin‐17, interleukin‐6, and sTNFR1.

![Increased cytokine production in virally suppressed HIV ^+^ participants on antiretroviral therapy is associated with hypertension. Cytokine production was analyzed in plasma using ELISA, including interleukin (IL)‐17 (**A**), IL‐6 (**B**), IL‐10 (**C**), tumor necrosis factor (TNF)‐α (**D**), TNF‐α receptor 2 (TNF‐αR2) (**E**), and TNF‐α receptor 1 (TNF‐αR1) (**F**). HTN indicates hypertensive; NT, normotensive. \**P*\<0.05, \*^\*^ *P*\<0.01 using the Mann‐Whitney *U* test.](JAH3-9-e011450-g002){#jah34782-fig-0002}

Elevated Eosinophils Were Associated With Increased Hypertension in Virally Suppressed PLWH {#jah34782-sec-0020}
-------------------------------------------------------------------------------------------

Prior studies have indicated that eosinophils play a role in several immune‐mediated diseases.[20](#jah34782-bib-0020){ref-type="ref"} As shown in Figure [3](#jah34782-fig-0003){ref-type="fig"}A, we found that among PLWH, participants with hypertension had a significantly higher percentage of eosinophils when compared with the normotensive participants. The absolute numbers of eosinophils were also similarly elevated in hypertensive PLWH when compared with normotensive participants (Figure [3](#jah34782-fig-0003){ref-type="fig"}B). The positive correlation between eosinophils and hypertension in virally suppressed PLWH remained significant after adjusting for age, sex, and FMI in a multivariate analysis (Table [2](#jah34782-tbl-0002){ref-type="table"}). We repeated a similar analysis using BMI instead of FMI, and eosinophils remained significantly associated with hypertension in PLWH (Table [S2](#jah34782-sup-0001){ref-type="supplementary-material"}). Notably, we found that the eosinophil maturation and differentiation factor interleukin‐5 was also associated with hypertension in virally suppressed HIV^+^ people in a univariate analysis (Figure [3](#jah34782-fig-0003){ref-type="fig"}C). This association was robust but did not reach statistical significance in the adjusted model (Table [2](#jah34782-tbl-0002){ref-type="table"}). The finding of both elevated circulating eosinophils and increased plasma levels of a key maturation factor strongly suggests that expansion of the eosinophil population may be a feature of hypertension in HIV. Given the small sample size, we performed goodness‐of‐fit analysis using the *P* values and the Nagelkerke *R* ^2^ as well as the C‐index analysis. Both these tests indicated goodness of fit (Tables [S3 and S4](#jah34782-sup-0001){ref-type="supplementary-material"}).

![Elevated eosinophils in blood are associated with increased hypertension. Analysis of eosinophils was performed using automated differential count of white blood cells and expressed as percentage (**A**) and absolute counts (**B**) in people living with HIV. Interleukin (IL)‐5 was analyzed using ELISA in plasma of people living with HIV (**C**). Eosinophil counts in HIV‐negative normotensive (NT) and hypertensive (HTN) participants in two different cohorts (**D**). \**P*\<0.01 using the Mann‐Whitney *U* test.](JAH3-9-e011450-g003){#jah34782-fig-0003}

###### 

Association Between Hypertension and Inflammatory Cell Subset/Biomarkers in HIV Using Logistic Regression Adjusted for FMI, Age, and Sex

  Variable               25% Quantile   75% Quantile   Value Difference (75%--25%)   *P* Value   Adjusted OR (75%--25%)   Adjusted OR (75%--25%, 95% CI)   *P* Value   
  ---------------------- -------------- -------------- ----------------------------- ----------- ------------------------ -------------------------------- ----------- -------
  Interleukin‐17         36.25          87             50.75                         0.056       1.4                      0.708                            2.766       0.333
  Interleukin‐6          2.282          5.743          3.46                          0.09        1.064                    0.492                            2.301       0.874
  TNFαR1                 9927.125       13 650.625     3723.5                        0.005       1.616                    0.817                            3.196       0.168
  MIP‐1α                 121.75         199.75         78                            0.025       1.905                    0.961                            3.775       0.065
  MCP1                   421.75         574.5          152.75                        0.094       1.458                    0.7                              3.036       0.313
  ICAM‐1                 445 708        646 911.125    201 203.125                   0.033       1.814                    0.821                            4.008       0.141
  VCAM1                  471 585.5      729.025        312.05                        0.04        1.733                    0.787                            3.815       0.172
  sCD163                 416.975        5.743          3.46                          0.09        1.064                    0.492                            2.301       0.874
  CD4^+^CD3^+^ T cells   5.3            10.3           5.6                           0.006       0.394                    0.158                            0.985       0.063
  Interleukin‐5          4.645          9.448          4.803                         0.013       1.988                    0.975                            4.055       0.059
  Eosinophils            1.1            2.7            1.6                           0.007       2.797                    1.106                            7.078       0.03
  Eosinophil %           1.787          2.659          0.872                         0.009       1.735                    0.804                            3.746       0.043

CD indicates cluster of differentiation; FMI, fat mass index; ICAM‐1, intercellular adhesion molecule 1; MCP1, monocyte chemoattractant protein 1; MIP‐1α, macrophage inflammatory protein‐1α; OR, odds ratio; sCD, soluble CD; TNFαR1, tumor necrosis factor‐α receptor 1; VCAM1, vascular cell adhesion molecule‐1.

To determine whether hypertension is also associated with elevated eosinophil counts in HIV‐negative individuals, we recruited an additional cohort of 50 HIV‐negative participants, including 25 normotensive and 25 hypertensive participants. Characteristics of these participants are shown in Table [S5](#jah34782-sup-0001){ref-type="supplementary-material"}. The eosinophil counts were obtained by retrospective review of the medical records for differential counts of white blood cells. We found that eosinophil counts were elevated in hypertensive when compared with normotensive people without HIV (Figure [3](#jah34782-fig-0003){ref-type="fig"}D). However, in a multivariate analysis after adjusting for sex, age, and BMI, eosinophil counts were not associated with hypertension, but they were significantly associated with increased BMI (Table [S6](#jah34782-sup-0001){ref-type="supplementary-material"}). In addition, we performed a regression analysis on the combined cohort comprising both the 70 HIV‐positive and the 50 HIV‐negative individuals. The clinical characteristics for the combined group are shown in Table [S7](#jah34782-sup-0001){ref-type="supplementary-material"}. After multivariate analysis of this combined cohort, controlling for age, sex, and BMI, the association between eosinophils and hypertension was robust but did not reach statistical significance (Table [S8](#jah34782-sup-0001){ref-type="supplementary-material"}).

In additional studies, we used the Synthetic Derivative, a Vanderbilt University Medical Center database of \~2.5×10^6^ deidentified electronic medical records, to identify additional HIV‐negative normotensive and hypertensive participants. We excluded participants who did not have information on eosinophil counts, those who were diabetic, and those with a history of acute coronary events, stroke, known rheumatologic or inflammatory conditions, or concomitant comorbidities that might modify eosinophil counts (allergic rhinitis, asthma, dermatoses, and parasitic disease). Pediatric subjects, who constitute a large number of the Vanderbilt Synthetic Derivative, were also excluded. The clinical characteristics for this cohort are shown in Table [S9](#jah34782-sup-0001){ref-type="supplementary-material"}. We found that hypertensive HIV‐negative subjects had a significantly higher eosinophil count when compared with the normotensive subjects (Figure 3D 165.81±1.29 \[n=9725 hypertensive subjects\] versus 151.97±0.49 \[n=71 314 normotensive subjects\]; *P*\<0.0001). However, like our smaller cohort of 50 HIV‐negative participants, higher eosinophil count was significantly corelated with the higher BMI in the hypertensive participants (*P*\<0.000001). The eosinophil count remained significantly associated with hypertension after a multivariate analysis (Table [S10](#jah34782-sup-0001){ref-type="supplementary-material"}).

We performed an additional analysis combining the HIV‐positive and HIV‐negative cohorts to determine the interaction between elevated eosinophils and HIV. This analysis confirmed that elevated eosinophils were significantly associated with hypertension (*P*=0.045) in the HIV‐positive cohort, but not significant in HIV‐negative cohort (*P*=0.41) (Table [S11](#jah34782-sup-0001){ref-type="supplementary-material"} and Figure [S3](#jah34782-sup-0001){ref-type="supplementary-material"}). The prediction results with one unit increase of eosinophilia in HIV‐positive and HIV‐negative cohorts are shown in Table [S12](#jah34782-sup-0001){ref-type="supplementary-material"}. These results suggest that unlike in HIV‐negative participants, in whom higher BMI explains the elevated eosinophil counts, HIV infection is accompanied by adipose tissue dysfunction that could mimic obesity, and this may increase eosinophil counts in HIV even without increase in BMI.

Discussion {#jah34782-sec-0021}
==========

In the current studies, we found that virally suppressed hypertensive PLWH and on ART exhibited higher levels of circulating eosinophils and their maturation marker interleukin‐5. They also had higher levels of inflammatory cytokines, including TNF‐α1, interleukin‐6, and interleukin‐17, when compared with normotensive controls. In addition, ICAM‐1 and MIP‐1α were elevated in hypertensive PLWH. After adjustment for multiple clinical and demographic factors, the circulating eosinophil counts remained significantly associated with hypertension in this population. However, elevated eosinophil counts were not significantly associated with hypertension in HIV‐negative participants after adjusting for multiple clinical and demographic factors.

Our results are summarized in Figure [4](#jah34782-fig-0004){ref-type="fig"}, in which we propose that HIV infection and/or ART is/are associated with increased endothelial dysfunction, with increased expression of vascular cell adhesion molecule‐1 and ICAM‐1. This increases the propensity of activated monocytes, with increased production of sCD163, to diapedese into tissues where they encounter dysfunctional adipose tissue and convert into activated macrophages and dendritic cells. The activated antigen‐presenting cells, including macrophages and dendritic cells, produce MCP1, which further increases migration and infiltration of monocyte/macrophages into tissues. They also produce chemotactic cytokine MIP‐1a, which activates eosinophils and induces release of interleukin‐6 and TNF‐α from macrophages and dendritic cells. These antigen‐presenting cells activate T cells to produce interleukin‐17, which contributes to hypertension. They also produce interleukin‐5, which induces differentiation of eosinophils. Thus, these findings suggest an association between higher eosinophil levels, potentially driven by elevated plasma interleukin‐5, and hypertension in HIV‐positive but not HIV‐negative people. The causal relationship between increased interleukin‐5 and eosinophils in inducing hypertension is not known.

![Hypothesized model summarizing all the inflammatory components associated with hypertension in people living with HIV. HIV infection and/or antiretroviral therapy (ART) is/are associated with increased endothelial dysfunction with increased expression of vascular cell adhesion molecule‐1 (VCAM‐1) and intracellular adhesion molecule 1 (ICAM‐1). This increases the propensity of activated monocytes, with increased production of soluble cluster of differentiation (sCD) 163, to diapedese into tissues where they encounter dysfunctional adipose tissue and convert into activated macrophages and dendritic cells. The activated antigen‐presenting cells, including macrophages and dendritic cells, produce MCP1 (monocyte chemoattractant protein 1), which further increases migration and infiltration of monocyte/macrophages into tissues. They also produce chemotactic cytokine MIP‐1α (macrophage inflammatory protein‐1α), which activates eosinophils and induces release of interleukin (IL)‐6 and tumor necrosis factor (TNF)‐α from macrophages and dendritic cells. These antigen‐presenting cells activate T cells to produce IL‐17, which contributes to hypertension. They also produce IL‐5, which induces differentiation of eosinophils. TNF‐αR1 indicates TNF‐α receptor 1.](JAH3-9-e011450-g004){#jah34782-fig-0004}

Although ART has significantly increased life expectancy among PLWH, there is now increased risk for hypertension and cardiovascular disease.[5](#jah34782-bib-0005){ref-type="ref"}, [21](#jah34782-bib-0021){ref-type="ref"} In humans, observational studies have reported a higher prevalence of hypertension in HIV‐positive people compared with the general population.[5](#jah34782-bib-0005){ref-type="ref"}, [22](#jah34782-bib-0022){ref-type="ref"} Recent studies suggest that HIV infection and its treatment with ART may play a role in the development of hypertension.[22](#jah34782-bib-0022){ref-type="ref"} One contributor may be the accumulation of central adiposity because of effects of both primary infection and antiretroviral agents on fat distribution. Notably, hypertensive people had similar quantities of fat mass in the lower extremities compared with normotensive people, but significantly higher quantities of android and truncal fat. Together, these findings likely represent a lipodystrophy phenotype characterized by central lipohypertrophy without a pronounced limb lipoatrophy, potentially reflecting the limitation of enrollment to people on efavirenz/tenofovir disoproxil fumarate/emtricitabin as opposed to older thymidine analogue medications (eg, zidovudine or stavudine). Although the accumulation of central adiposity may contribute to inflammation, the HIV‐specific inflammatory factors predisposing to hypertension are poorly understood. Herein, we found some similarity as well as unique immune components associated with hypertension in PLWH when compared with the general population.

An interesting finding of the present study is that elevated blood pressure in PLWH was associated with low levels of CD38 expression on CD4^+^ T cells, which is a transmembrane glycoprotein indicating T‐cell activation. Prior studies have found that lower percentages and absolute numbers of CD4^+^CD38^+^ T cells were associated with severe HIV disease pathogenesis and immunologic deterioration in children perinatally infected with HIV and surviving for \>5 years.[23](#jah34782-bib-0023){ref-type="ref"} We found no significant difference in expression of CD38 on CD8^+^ T cells in hypertensive versus normotensive subjects, which has been found to be a marker of residual virus replication in chronically HIV‐infected patients receiving Combination Antiretroviral Therapy.[24](#jah34782-bib-0024){ref-type="ref"} Indeed, all participant in the current studies had been virally suppressed (viral load\<50 copies/mL limit of detection) for a minimum 12 months before the study. Further research is needed to determine the role of CD4^+^ T cells expressing CD38 and how they may interact with other immune cells in the setting of hypertension in HIV‐positive individuals.

We found that monocyte/macrophage activation was associated with hypertension in PLWH. This was indicated by a marked increase in the shedding of the hemoglobin‐haptoglobin scavenger receptor CD163 into the circulation as sCD163 by the activated macrophages and monocytes. In addition, we found increased MIP‐1α and MCP in hypertensive when compared with normotensive PLWH. Our current findings are in keeping with increasing evidence indicating that cells of the innate immune system, including monocytes and macrophages, play a role in the pathogenesis of hypertension. Previous studies have found that activated macrophages contribute to hypertension and deletion of monocytes markedly reduces experimental hypertension.[25](#jah34782-bib-0025){ref-type="ref"}, [26](#jah34782-bib-0026){ref-type="ref"}, [27](#jah34782-bib-0027){ref-type="ref"} Macrophages accumulate in the kidney and the vasculature in experimental models of hypertension and promote hypertension.[28](#jah34782-bib-0028){ref-type="ref"}, [29](#jah34782-bib-0029){ref-type="ref"} Moreover, we found that hypertension in PLWH was associated with increased expression of adhesion molecules, including vascular cell adhesion molecule‐1 and ICAM‐1, which govern migration and infiltration of immune cells into tissues and have been implicated in the pathogenesis of hypertension in experimental animal models.[30](#jah34782-bib-0030){ref-type="ref"}

A notable finding of our current study is that hypertension in PLWH was associated with increased cytokine production and signaling, including interleukin‐6, TNF‐α, and interleukin‐17. Previous studies have found that T cells and their cytokines contribute to hypertension.[31](#jah34782-bib-0031){ref-type="ref"}, [32](#jah34782-bib-0032){ref-type="ref"} Mice lacking T cells (recombination‐activating gene‐1^−/−^ mice) and mice lacking the T‐cell cytokine interleukin‐17A develop blunted hypertension.[17](#jah34782-bib-0017){ref-type="ref"}, [33](#jah34782-bib-0033){ref-type="ref"} We previously found that hypertension augments the capacity of dendritic cells to produce interleukin‐6 and these polarized T cells to produce interleukin‐17 and TNF‐α.[16](#jah34782-bib-0016){ref-type="ref"}, [34](#jah34782-bib-0034){ref-type="ref"} Thus, hypertension in PLWH is associated with some inflammatory components similar to those that have been implicated in hypertension in the general population.

In this cohort of virally suppressed PLWH, eosinophils were significantly associated with hypertension, independent of age, sex, and adiposity. Interleukin‐5 and eosinophils have been implicated in several inflammatory conditions, including asthma, drug hypersensitivity, neoplastic disorders, and helminths infections.[35](#jah34782-bib-0035){ref-type="ref"} Interleukin‐5 is produced by T helper 2 cells, mast cells, γδT cells, natural killer, and natural killer T cells and other nonhematopoietic cells.[36](#jah34782-bib-0036){ref-type="ref"}, [37](#jah34782-bib-0037){ref-type="ref"}, [38](#jah34782-bib-0038){ref-type="ref"}, [39](#jah34782-bib-0039){ref-type="ref"}, [40](#jah34782-bib-0040){ref-type="ref"} It was originally identified as a T‐cell--derived cytokine involved in antibody production from B cells.[38](#jah34782-bib-0038){ref-type="ref"} Recently, interleukin‐5 has been implicated in mediating maturation and differentiation of eosinophils in mice and humans.[38](#jah34782-bib-0038){ref-type="ref"} In addition, eosinophils play a controversial role in obesity‐mediated inflammation.[41](#jah34782-bib-0041){ref-type="ref"}, [42](#jah34782-bib-0042){ref-type="ref"} In the LifeLines Cohort Study of \>13 000 members of the general population in Europe, higher eosinophil counts were associated with higher triglycerides, total cholesterol, and hemoglobin A1c, but lower high‐density lipoprotein, in addition to a higher odds of obesity and metabolic syndrome.[43](#jah34782-bib-0043){ref-type="ref"} Despite this association between eosinophils and cardiometabolic disease, no prior studies have found any association between eosinophils and hypertension.

Our results indicate that although eosinophil counts are elevated in hypertensive PLWH independent of BMI, they are dependent on BMI in HIV‐negative people. Previously, eosinophils were thought to be only associated with Th2 inflammatory disorders, including parasitic infections and allergic reactions.[44](#jah34782-bib-0044){ref-type="ref"} However, recent studies have found that eosinophils can infiltrate adipose tissue and regulate its function.[41](#jah34782-bib-0041){ref-type="ref"} Wither et al found that eosinophils play a role in obesity‐related hypertension, where they regulate perivascular adipose tissue and vascular function.[45](#jah34782-bib-0045){ref-type="ref"} Mice lacking eosinophils do not elicit an anticontractile effect resulting from adiponectin and adipocyte‐derived NO.[46](#jah34782-bib-0046){ref-type="ref"} This effect mimics the obese phenotype and is restored by reconstitution of eosinophils. The role of eosinophils in hypertension in the setting of HIV infection is not known. Acquired lipodystrophy occurs in 60% to 80% of patients with HIV on cART,[47](#jah34782-bib-0047){ref-type="ref"} and is associated with endothelial dysfunction leading to cardiovascular disease.[48](#jah34782-bib-0048){ref-type="ref"}, [49](#jah34782-bib-0049){ref-type="ref"}, [50](#jah34782-bib-0050){ref-type="ref"}, [51](#jah34782-bib-0051){ref-type="ref"} Thus, it is likely that although elevated eosinophil counts were independent of increased BMI in the hypertensive PLWH, they may be associated with acquired lipodystrophy, which creates a metabolic milieu similar to increased BMI. Understanding how eosinophils impact cardiovascular function and hypertension may have important implications for the treatment of metabolic disorders associated with obesity and HIV.

Eosinophils have been found to regulate macrophage activation in adipose tissue. Wu et al[41](#jah34782-bib-0041){ref-type="ref"} found that in mice, eosinophils are major producers of interleukin‐4 in white adipose tissues and increase infiltration of alternatively activated macrophages. Mice fed a high‐fat diet develop increased body fat, impaired glucose tolerance, and insulin resistance in the absence of eosinophils. These studies suggest that eosinophils play a role in metabolic homeostasis through maintenance of adipose alternatively activated macrophages. Indeed, we found that macrophage activation factors, including MIP‐1α, were elevated in hypertensive PLWH. However, unlike in the HIV‐negative participants, we found that eosinophil counts are increased in HIV independent of BMI. It is not clear what role these cells play in hypertension associated with HIV and whether they contribute to macrophage activation. Moreover, peripheral blood eosinophilia is often observed in patients with chronic kidney disease, those with acute kidney injury, or patients on renal replacement therapy, and this may be associated with bioincompatibility of the dialysis material, acute allograft rejection, or *Strongyloides* hyperinfection. Further scientific effort is required to determine if eosinophilia is associated with kidney disease in hypertensive PLWH.[52](#jah34782-bib-0052){ref-type="ref"}

Our results suggest an association between higher eosinophil levels, potentially driven by elevated plasma interleukin‐5, and hypertension in PLWH. This association is present but abrogated by BMI in HIV‐negative hypertensive people. The findings that eosinophils and their maturation cytokine interleukin‐5 are elevated in hypertensive PLWH are interesting but only hypothesis generating and do not confirm any new pathogenesis of hypertension. However, these 2 related findings provide a pragmatic and strong rationale to study this pathway further in either hypertension or hypertension in HIV.

There is evidence that CD8^+^ T cells activated in presence of interleukin‐4 can exhibit a Th2‐like phenotype and produce cytokines interleukin‐4, interleukin‐5, interleukin‐6, and interleukin‐10. The role of CD8^+^ T cells in the context of the HIV‐1 infection is not fully understood; however, it is possible that they are responsible for production of high levels of interleukin‐5,[53](#jah34782-bib-0053){ref-type="ref"}, [54](#jah34782-bib-0054){ref-type="ref"} which may drive the eosinophilia. Although we did not observe any significant differences in CD8^+^ T cells between normotensive and hypertensive PLWH, previous studies have found that adipose tissue from PLWH is enriched for CD8^+^ T cells compared with HIV‐negative controls; and similar changes seen have been observed in obesity.[55](#jah34782-bib-0055){ref-type="ref"}, [56](#jah34782-bib-0056){ref-type="ref"} This role for CD8^+^ T cells in interleukin‐5 production does raise the possibility that the elevated eosinophils we observed in hypertensive PLWH may not represent a causal mechanism, but rather be a reflection of a link between the CD8^+^ T‐cell antiviral immune response and cardiovascular function. In keeping with this concept, absence of eosinophils has been associated with worsening of cardiometabolic health and restoration of eosinophils leads to increased vascular relaxation and improved glucose homeostasis.[41](#jah34782-bib-0041){ref-type="ref"} However, other studies have failed to demonstrate an effect of these cells in rescuing metabolic impairment,[42](#jah34782-bib-0042){ref-type="ref"} and Amini et al found that higher eosinophil counts were associated with risk factors of metabolic syndrome, including higher triglycerides, total cholesterol, and hemoglobin A1c.[43](#jah34782-bib-0043){ref-type="ref"} Studies have found increased levels of other cells known to be anti‐inflammatory, such as T‐regulatory cells in disease. For example, T‐regulatory cells are increased in the circulation of patients with idiopathic pulmonary arterial hypertension.[57](#jah34782-bib-0057){ref-type="ref"}, [58](#jah34782-bib-0058){ref-type="ref"} Thus, anti‐inflammatory cells may become dysfunctional during disease pathogenesis. Further research is needed to determine how the function of eosinophils may be affected during hypertension in HIV.

In summary, we discovered a significant association between elevated eosinophils and hypertension that might represent a novel pathway leading to hypertension in HIV‐infected adults. Further research is needed to determine the specific contribution of the HIV‐positive status versus ART on inflammation and how they may contribute to hypertension and cardiovascular disease. We acknowledge that this is a cross‐sectional study in a limited cohort of 70 HIV‐positive participants and therefore cannot address causality. Although our findings obviously warrant further validation, we believe there is clinical utility for treatment of hypertension in or outside the context of HIV.
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**Figure S1.** Increased CD4 T cell activation in people living with HIV is negatively associated with hypertension. Flow cytometry analysis of T cell subsets in people living with HIV showing (**A**) naïve and (**B**) memory CD4+ and CD8+T cell subtypes, (**C**) T cells expressing CD57, (**D**) PD1, (**E**) CD38and (**F**) the CD38 receptor in normotensives compared to hypertensives. \*\*^\*^ *P*\<0.001.

**Figure S2.** Gating strategy to identify T cell subtypes.

**Figure S3.** Analysis combining the HIV positive and negative cohorts to determine the Interaction between elevated eosinophils and HIV. Log odds of elevated eosinophils in HIV positive and negative cohort (*P*=0.045 in the HIV positive cohort and *P*=0.41 in the HIV negative cohort).

**Table S1**. Fat Mass Measurements Between Hypertensives and Normotensive

**Table S2.** Association Between Hypertension and Inflammatory Cell Subset/Biomarkers in HIV Using Logistic Regression Adjusted for Body Mass Index, Age, and Sex

**Table S3.** Analysis of *P* Values of Model Likelihood Ratio chi‐square test and Nagelkerke *R* ^2^ Index. Most of the Interesting Variables Have *P*\<0.01 and *R* ^2^\>0.3, Which Indicated the Goodness of Fit for the HIV‐Positive Cohort

**Table S4.** Analysis of C‐Index to Measure Goodness of Fit. All variables of interest have C‐index \>0.75 indicating goodness of fit. See last column (C) of each Table

**Table S5.** Demographics and Clinical Data for HIV‐Negative Subjects

**Table S6.** Association Between Hypertension and Demographic and Clinical Characteristics in the HIV‐Negative Cohort Using Logistic Regression Adjusted for Body Mass Index, Age, and Sex

**Table S7.** Demographics and Clinical Data for Both the 50 HIV‐Negative and 70 HIV‐Positive Cohorts Combined

**Table S8.** Association Between Hypertension and Demographic/Clinical Characteristics in the Both the 50 HIV‐Negative and 70 HIV‐Positive Cohorts Logistic Regression

**Table S9.** Demographics and Clinical Data for the Confirmatory HIV‐Negative Cohort From the Synthetic Derivative

**Table S10.** Association Between Hypertension and Demographic and Clinical Characteristics in the HIV‐Negative Cohort From the Synthetic Derivative Using Logistic Regression

**Table S11.** Model Result Analysis Combining the HIV Positive and Negative Cohorts to Determine the Interaction Between Elevated Eosinophils and HIV

**Table S12.** Prediction Results With One Unit Increase of Eosinophilia in HIV Positive and Negative Cohorts
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Click here for additional data file.
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